Although the application of [177Lu]Lu-PSMA-targeting radioligand therapy in treating DTC patients has been limited, parallels can be drawn with the experiences of prostate cancer patients in terms of toxicity [46]. This evidence concerns the gene FOLH1 and prostate carcinoma.